Cargando…

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents. ABT-869, a novel ATP-competitive receptor tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jianbiao, Goh, Boon-Cher, Albert, Daniel H, Chen, Chien-Shing
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729745/ https://www.ncbi.nlm.nih.gov/pubmed/19642998 http://dx.doi.org/10.1186/1756-8722-2-33

Ejemplares similares

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS
por: Iqbal, Muzaffar, et al.
Publicado: (2014)

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
por: Wu, Jingjing, et al.
Publicado: (2016)

Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer
por: Chen, Jing, et al.
Publicado: (2016)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
por: Asahina, Hajime, et al.
Publicado: (2012)

Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond
por: Ma, Terry King-Wing, et al.
Publicado: (2017)

Bench-to-bedside review: Fulfilling promises of the Human Genome Project
por: Chiche, Jean-Daniel, et al.
Publicado: (2002)

Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)

B-Raf and the inhibitors: from bench to bedside
por: Huang, Tiangui, et al.
Publicado: (2013)

RTK Inhibitors in Melanoma: From Bench to Bedside
por: Sabbah, Malak, et al.
Publicado: (2021)

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside
por: Saburi, Ehsan, et al.
Publicado: (2017)

LECT2: A pleiotropic and promising hepatokine, from bench to bedside
por: Xie, Yuan, et al.
Publicado: (2022)

Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
por: Olivieri, Jacopo, et al.
Publicado: (2011)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors
por: Gardner, Christopher R., et al.
Publicado: (2023)

Bench-to-bedside review: Adenosine receptors – promising targets in acute lung injury?
por: Schepp, Carsten P, et al.
Publicado: (2008)

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside
por: Hu, Mengyuan, et al.
Publicado: (2023)

Bedside to bench and back to bedside: Translational implications of targeted intervertebral disc therapeutics
por: Rosenberg, Gary Joel, et al.
Publicado: (2017)

Sepsis: From Bench to Bedside
por: Silva, Eliézer, et al.
Publicado: (2008)

Sonochemotherapy: from bench to bedside
por: Lammertink, Bart H. A., et al.
Publicado: (2015)

Nutrition: From Bench to Bedside
por: Khan, Naim A., et al.
Publicado: (2016)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Pruritus: From the Bench to the Bedside
por: Reich, Adam, et al.
Publicado: (2018)

Silver linings at the bench and bedside
por: Katz, Steven C., et al.
Publicado: (2020)

Olutasidenib: from bench to bedside
por: Venugopal, Sangeetha, et al.
Publicado: (2023)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

Efflux pump inhibitors for bacterial pathogens: From bench to bedside
por: Sharma, Atin, et al.
Publicado: (2019)

Bench-To-Bedside and Bedside Back to the Bench; Coordinating Clinical and Experimental Traumatic Brain Injury Studies
por: Agoston, Denes V., et al.
Publicado: (2012)

Bench-to-bedside review: An approach to hemodynamic monitoring - Guyton at the bedside
por: Magder, Sheldon
Publicado: (2012)

Research in Sickle Cell Disease: From Bedside to Bench to Bedside
por: Salinas Cisneros, Gabriel, et al.
Publicado: (2021)

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
por: Feng, Yimei, et al.
Publicado: (2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021)

Cancer proteomics: from bench to bedside
por: Timms, J F
Publicado: (2008)

Bench-to-bedside review: Metabolism and nutrition
por: Casaer, Michaël P, et al.
Publicado: (2008)

Bench-to-bedside review: Permissive hypercapnia
por: O' Croinin, Donall, et al.
Publicado: (2005)

DNA sequencing: bench to bedside and beyond(†)
por: Hutchison, Clyde A.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_7o0lmo1hm5577p5731g3hn5edg